Molecular imaging company Blue Earth Diagnostics has completed the first commercial delivery of its Axumin (fluciclovine F-18) PET radiopharmaceutical in Slovakia.
The delivery was made in partnership with MGP, Blue Earth's distributor in Slovakia, according to the vendor. With the expansion into Slovakia, Axumin is now available in nine countries in the European Union (EU), including Belgium, Luxembourg, Italy, France, Norway, the Czech Republic, the Netherlands, and Austria.
Axumin is approved in the EU for use in men with suspected recurrence of prostate cancer.
